CPT1B rs5770917: Genetic Variant and Narcolepsy Susceptibility
The rs5770917 polymorphism is a single-nucleotide variant located in an intergenic region on chromosome 22 near the CPT1B and CHKB genes. Genome-wide association studies first identified the variant as a statistical susceptibility marker for narcolepsy and daytime hypersomnia, particularly in East Asian cohorts. The variant allele correlates with altered gene expression in fatty acid metabolism pathways, though its overall predictive power remains limited outside specific population contexts.
What each genotype means
Increased narcolepsy susceptibility
This genotype is associated with a higher statistical risk for narcolepsy and other hypersomnias compared to the T allele. Research indicates that this variant may suppress the expression of the CPT1B gene, which is involved in fatty acid metabolism. Please consult with a healthcare professional if you have concerns about sleep patterns or daytime sleepiness.
This genotype is most common in East Asian populations and is significantly less frequent in individuals of European ancestry.
Elevated narcolepsy risk
Carrying one copy of the C allele is associated with an increased statistical risk for narcolepsy compared to those with the T/T genotype. This variant is linked to reduced CPT1B gene expression, which may influence fatty acid metabolism. If you experience persistent daytime sleepiness or other sleep-related symptoms, please discuss them with your clinician.
This heterozygous genotype is found at varying frequencies globally, being more prevalent in East Asian populations than in European populations.
Typical risk profile
This genotype is considered the baseline or normal state for this variant in relation to narcolepsy susceptibility. It is not associated with the reduced CPT1B expression observed with the C allele. This result does not rule out other genetic or environmental factors that may influence sleep health.
This is the most common genotype in populations of European ancestry and is also present in East Asian populations.
Genomic Location and Variant Characteristics
The single-nucleotide polymorphism rs5770917 is mapped to chromosome 22q13.33 in the intergenic segment situated between the carnitine palmitoyltransferase 1B (CPT1B) and choline kinase beta (CHKB) genes. At this genomic locus, an individual may inherit either a cytosine (C) or a thymine (T) allele. Because rs5770917 resides in a non-coding genomic spacer rather than an exon, it does not directly alter the amino acid sequence of any protein. Instead, functional genomic analyses indicate that rs5770917 functions as a regulatory quantitative trait locus (eQTL). The presence of the risk-associated C allele has been shown to correlate with decreased messenger RNA (mRNA) expression levels of both neighboring genes in circulating white blood cells. This positioning highlights how non-coding regulatory variants can influence the transcriptional output of physically adjacent metabolic genes without modifying their core structural sequences.
Biological Role of CPT1B and CHKB
The CPT1B gene encodes the muscle isoform of carnitine palmitoyltransferase 1, a rate-limiting mitochondrial outer membrane enzyme essential for the carnitine shuttle system. This enzyme conjugates long-chain fatty acids to carnitine, allowing them to cross mitochondrial membranes to undergo beta-oxidation for cellular energy production. Impaired fatty acid oxidation has been hypothesized to influence rapid eye movement (REM) sleep architecture and neurological energy homeostasis. The neighboring CHKB gene encodes choline kinase beta, an enzyme that catalyzes the initial phosphorylation step in the biosynthesis of phosphatidylcholine, a key membrane phospholipid. Choline metabolism also intersects with pathways governing the synthesis of acetylcholine, a neurotransmitter centrally involved in regulating REM sleep states and wakefulness. Consequently, regulatory shifts at this locus bridge metabolic lipid processing and neurochemical signaling.
Scientific Evidence and Strength of Narcolepsy Association
In 2008, a landmark Japanese genome-wide association study (GWAS) identified the C allele of rs5770917 as a novel susceptibility marker for narcolepsy with cataplexy, demonstrating an odds ratio of approximately 1.79. Later research noted statistical ties between the variant and other related hypersomnia phenotypes. Subsequent investigations revealed that individuals carrying the C allele exhibited lowered CPT1B expression alongside abnormal serum acylcarnitine profiles, suggesting systemic mitochondrial metabolic changes. However, replication efforts in broader global cohorts have yielded mixed results. While replicated in Korean cohorts, the association failed to reach statistical significance in certain European and Chinese samples. Because the primary genetic driver of narcolepsy remains the major histocompatibility complex (specifically the HLA-DQB1*06:02 haplotype), rs5770917 confers only modest, population-dependent susceptibility rather than deterministic causality.
Ancestry and Population Frequencies
The distribution of rs5770917 varies substantially across world ancestries. The narcolepsy-associated C allele is relatively common in East Asian populations, demonstrating a minor allele frequency (MAF) of approximately 18% to 20% in Japanese and Korean cohorts. In sharp contrast, public genomic databases such as the Genome Aggregation Database (gnomAD) indicate that the C allele is uncommon in populations of European descent, with an estimated allele frequency of around 1%. Allele frequencies in African and South Asian cohorts similarly demonstrate significant divergence. These stark epidemiological variations explain why genome-wide association studies conducted in European cohorts often lack statistical power to evaluate or replicate this signal, emphasizing that genetic susceptibility architectures for complex neurological traits can differ markedly depending on an individual's ancestral background.
Clinical Interpretation and Limitations
Genotype information for rs5770917 is primarily an educational and research tool and should not be used as a standalone diagnostic test for narcolepsy or excessive daytime sleepiness. Narcolepsy is a complex neurological disorder primarily caused by the autoimmune destruction of hypocretin-producing neurons in the hypothalamus, driven by high-risk HLA alleles and environmental triggers. Having one or two copies of the rs5770917 C allele does not mean a person will develop narcolepsy, nor does possessing the TT genotype guarantee protection. While experimental studies have explored compounds like L-carnitine to support fatty acid oxidation pathways, dietary or therapeutic decisions must never be guided solely by consumer genetic results. Anyone experiencing unexplained daytime sleepiness, sudden muscle weakness (cataplexy), or sleep disruption should consult a sleep specialist for comprehensive polysomnography and clinical evaluation.
How common is this variant?
The rs5770917 minor C allele is common in East Asian populations with an estimated frequency of approximately 18%, but it is uncommon in European populations with an allele frequency of around 1% according to gnomAD datasets.
Frequently asked questions
Does having the rs5770917 C allele mean I have narcolepsy?
No, carrying the C allele is not a diagnosis. Narcolepsy is a rare neurological disorder, and rs5770917 confers only a slight statistical increase in susceptibility, primarily documented in East Asian studies. Most people with the C allele never develop sleep disorders.
What does the CPT1B gene do in the body?
The CPT1B gene provides instructions for making carnitine palmitoyltransferase 1B, an enzyme essential for transporting long-chain fatty acids into mitochondria to be burned for cellular energy. Altered expression of this enzyme can impact metabolic pathways that intersect with sleep regulation.
Why are the study results different between European and East Asian groups?
The frequency of the rs5770917 C allele is markedly different across ancestries, occurring in roughly 18% of East Asian genomes but only about 1% of European genomes. Differences in surrounding linkage disequilibrium and genetic background mean that statistical associations found in one ancestral group do not always replicate in others.
Should I take carnitine supplements if I carry the C allele?
You should not start dietary supplements solely based on an rs5770917 genotype result. While clinical researchers have studied carnitine metabolism in narcolepsy, evidence supporting general over-the-counter supplementation is limited, and any therapeutic plan should be discussed directly with a qualified healthcare professional.
Sources & further reading
Educational information only, last refreshed 9/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs5770917?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29